Zealand Pharma’s Petrelintide: A New Era in Obesity Treatment?
Recent Phase 2 trial results for petrelintide, developed in collaboration between Zealand Pharma and Roche, are generating significant buzz in the pharmaceutical industry. The data, revealed on March 5, 2026, demonstrate a mean weight loss of up to 10.7% at 42 weeks, compared to 1.7% in the placebo group. This promising outcome, coupled with a placebo-like tolerability profile, positions petrelintide as a potential game-changer in the fight against obesity.
The Science Behind Petrelintide: An Amylin Analog
Petrelintide is an amylin analog, a type of medication that mimics the effects of the naturally occurring hormone amylin. Amylin plays a role in regulating appetite and slowing gastric emptying, contributing to feelings of fullness. Unlike some existing weight loss medications, petrelintide has shown a remarkably favorable tolerability profile in trials, with no reported cases of vomiting at the most effective dose.
Market Reaction and Analyst Perspectives
The initial market reaction to the Phase 2 results has been mixed. While the efficacy data is encouraging, some analysts have expressed caution. Nordea downgraded its recommendation for Zealand Pharma from “Buy” to “Hold,” citing questions about how petrelintide differentiates itself from existing GLP-1 receptor agonists. This downgrade contributed to a significant drop in Zealand Pharma’s stock price, falling around 30% in early trading on the Copenhagen Stock Exchange.
Jefferies, however, maintains a “Buy” recommendation, albeit with a revised outlook. They suggest the market is currently pricing in peak sales of less than $1.5 billion, significantly lower than their initial estimate of $6 billion. Jefferies also believes petrelintide will likely be positioned as the second-best alternative to Eli Lilly’s Eloralintid.
Roche’s Strategic Investment and Future Development
Roche entered into an exclusive collaboration and licensing agreement with Zealand Pharma in March 2025 to co-develop and co-commercialize petrelintide. The agreement includes upfront payments of $1.65 billion to Zealand Pharma, with potential milestone payments bringing the total consideration to up to $5.3 billion. Profits and losses will be shared equally in the U.S. And Europe, while Zealand Pharma will receive royalties on sales in the rest of the world.
The collaboration also encompasses the development of a fixed-dose combination of petrelintide and CT-388, Roche’s lead incretin asset. This combination therapy aims to leverage the complementary mechanisms of action of amylin analogs and incretins to achieve even greater weight loss and metabolic benefits.
The Growing Obesity Market and the Need for Innovation
Obesity is a global health crisis, projected to impact over 4 billion people by 2035. The market for obesity treatments is therefore expanding rapidly, driven by the increasing prevalence of the disease and a growing awareness of its associated health risks, including cardiovascular disease, type 2 diabetes, and certain cancers. The need for effective and well-tolerated therapies is paramount.
Did you know? Obesity is a heterogeneous disease with over 200 related comorbidities.
Looking Ahead: Phase 3 Trials and Beyond
Zealand Pharma plans to initiate Phase 3 trials later in 2026. These trials will be crucial in confirming the efficacy and safety of petrelintide in a larger and more diverse patient population. Success in Phase 3 could pave the way for regulatory approval and commercial launch, potentially transforming the treatment landscape for individuals struggling with overweight and obesity.
FAQ
Q: What is petrelintide?
A: Petrelintide is an amylin analog being developed for the treatment of obesity.
Q: What were the key results of the Phase 2 trial?
A: The trial showed up to 10.7% mean weight loss at 42 weeks, compared to 1.7% with placebo, and a placebo-like tolerability profile.
Q: Who is collaborating on the development of petrelintide?
A: Zealand Pharma and Roche are collaborating on the co-development and co-commercialization of petrelintide.
Q: What is the expected timeline for Phase 3 trials?
A: Phase 3 trials are planned to begin later in 2026.
Pro Tip: Managing obesity often requires a multifaceted approach. Combining medication with lifestyle changes, such as diet and exercise, can maximize results.
Stay informed about the latest developments in obesity treatment. Explore more articles on metabolic health or subscribe to our newsletter for regular updates.
